Mucin 6/MUC6 CRISPR/Cas9 KO Plasmid (h): sc-402946
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Mucin 6/MUC6 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Mucin 6/MUC6 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Mucin 6/MUC6 Antibody (CLH5): sc-33668
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Mucin 6/MUC6 CRISPR/Cas9 KO Plasmid (h) | sc-402946 | 20 µg | $397.00 |
Overview
MUC6 encodes mucin 6, a secreted, heavily O-glycosylated gel-forming mucin that contributes to the protective mucus barrier on epithelial surfaces. Through its extensive glycan structures and polymeric matrix formation, MUC6 helps regulate hydration, viscosity, and interactions with microbes and luminal factors, shaping mucosal homeostasis and innate defense. Its expression is linked to epithelial differentiation and mucin biosynthesis programs that interface with ER/Golgi glycosylation pathways and barrier maintenance processes. Dysregulated MUC6 expression and altered mucin glycosylation patterns are associated with inflammatory injury and epithelial remodeling in gastrointestinal and other mucosa-associated diseases, and are frequently evaluated as biomarkers of lineage and mucous cell states in cancer biology.
Mucin 6/MUC6 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the MUC6 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the MUC6 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the MUC6 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Mucin 6/MUC6 protein expression.
This CRISPR knockout system enables efficient generation of MUC6-deficient cell models for investigation of Mucin 6/MUC6 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting MUC6 exon(s) critical for Mucin 6/MUC6 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple MUC6 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Mucin 6/MUC6 CRISPR/Cas9 KO Plasmid (h) and Mucin 6/MUC6 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the MUC6 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Mucin 6/MUC6 HDR Plasmid (h) and Mucin 6/MUC6 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by MUC6 homology arms to support homology-directed repair at defined MUC6 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.